Corcept Therapeutics Incorporated - Common Stock - Çeyreklik Bilanço (NASDAQ:CORT) | MetaTrader

Tam grafiği aç Full chart

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

Haberler

Corcept yumurtalık kanseri tedavisi için sağkalım verilerini sundu

CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up

Corcept relacorilant başvurusunu FDA’ya yeniden sunacak

Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade

Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?

S&P 500 and Nasdaq 100 Post New Record Highs on Chip Stock Strength

Chip Stock Strength Lifts the Broader Market

Stocks Pressured by Signs of Resurgent Inflation

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement (NASDAQ:CORT)

H.C. Wainwright, Corcept hissesi için hedef fiyatı yükseltti

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates